ConcertAI has announced an agreement that will allow Bayer to utilise its Translational360 and AI software-as-a-service (SaaS) solutions to expedite clinical development in precision oncology using insights from AI and machine learning (ML).
The multi-year agreement will completely utilise Translational360, a recently introduced integrated research-grade longitudinal clinical molecular database.
Go deeper with GlobalData
This database incorporates de-identified oncology patient data from CancerLinQ, encompassing more than nine million records across all 50 US states.
ConcertAI notes that Translational360 merges genomic, clinical, transcriptomic and whole-slide imaging data from comprehensive molecular testing, offering genomic and phenotypical insights.
Transcriptomics, a key component of biopharma translational sciences, enables researchers to know the molecular mechanisms of diseases, patient response, and inter-patient variability.
These insights are crucial for the development of new therapeutics. By integrating data solutions and AI, the company aims to help choose programmes with the likelihood of success and to design studies that are informed by multi-genomic, transcriptomic, and multi-modal data.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataConcertAI CEO Jeff Elton said: “This partnership furthers causal biological inferences where multi-modal and multi-molecular data can be integrated with AI/ML-based approaches across discovery, translation, and development, accelerating oncology pipelines, allowing our biopharma partners to deliver better medicines faster.
“This partnership builds on a multi-year history of working together and is unique in offering both tissue and liquid biopsy molecular data, allowing insights into patterns of treatment response, acquisition of resistance, AI modelling of likely success and benefit, informing programme priority and clinical study design.”
Bayer Pharma research and development (R&D) Data Science and AI head Sai Jasti said: “By combining ConcertAI’s powerful data solutions with Bayer’s scientific and AI expertise, we aim to enhance the use of real-world data and cutting-edge AI to boost R&D productivity and ultimately deliver transformative precision therapies to those who need them.”
